Key result
Fenofibric acid plus statins improves overall lipid profiles better than statin monotherapy in mixed dyslipidemia.
Answers are grounded in this paper and cite their sources.
Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin. The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose. The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects. The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing.
No takes yet. Share an insight, caveat, or question.
Theodosios D. Filippatos (2012) conducted a review in Mixed dyslipidemia. Fenofibric acid combined with statin (simvastatin, atorvastatin, or rosuvastatin) vs. Corresponding statin dose monotherapy was evaluated on Improvement of overall lipid profile (triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein subspecies). Fenofibric acid combined with low- or moderate-dose statins resulted in greater improvement of the overall lipid profile compared with statin monotherapy in patients with mixed dyslipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: